The FDA warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson & Johnson and Eli Lilly in partnership with Boehringer Ingleheim may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones. Via Newsmax Health. Posted May 16, 2015.
–Alanna McCatty
